Nomura monitors the performance and stock of Dr Lal PathLabs, noting sustained traction in the Delhi NCR market.
2 reports, 1 independent
Updated Jul 27
Gone quiet
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Nomura monitors the performance and stock of Dr Lal PathLabs, noting sustained traction in the Delhi NCR market.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Nomura
corporation in Japan
-
Dr Lal PathLabs
public company
Nothing else this week.
Related events
- Nomura provided outlooks regarding the Indian auto market on May 28, 2026.
- Nomura is a Japanese financial services holding company.
- Nomura retained a buy rating, Morgan Stanley retained equal-weight, and CLSA downgraded Godrej Consumer Products stock.
- Nomura provided market analysis and rating on Mahindra & Mahindra Ltd. on August 17, 2026.
- Nomura is closely monitoring Voltas' financial performance, and the two companies have established a joint venture for the Indian market.
Coverage
Newest first; wire copies grouped- indiatimes.comDr Lal PathLabs shares soar 8% after Q1 earnings beat estimates. What Nomura, Nuvama, other brokerages are saying?
- indiatimes.com